What's new

Orphan designation: N-(2-Methoxyethyl)-6-methyl-N-[(3-methyl-2-thienyl)methyl]-2-oxo-1,2-dihydropyridine-4-carboxamide Treatment of glycogen storage disease type IV, 16/01/2025 Positive

Orphan designation: N-(2-Methoxyethyl)-6-methyl-N-[(3-methyl-2-thienyl)methyl]-2-oxo-1,2-dihydropyridine-4-carboxamide Treatment of glycogen storage disease type IV, 16/01/2025 Positive

Feb 20, 2025 - 15:10
 0
Orphan designation: N-(2-Methoxyethyl)-6-methyl-N-[(3-methyl-2-thienyl)methyl]-2-oxo-1,2-dihydropyridine-4-carboxamide Treatment of glycogen storage disease type IV, 16/01/2025 Positive
Orphan designation: N-(2-Methoxyethyl)-6-methyl-N-[(3-methyl-2-thienyl)methyl]-2-oxo-1,2-dihydropyridine-4-carboxamide Treatment of glycogen storage disease type IV, 16/01/2025 Positive
Read More

Tags:

Previous Article

Orphan designation: zopapogene imadenovec Treatment of recurrent respiratory pap...

Next Article

Human medicines European public assessment report (EPAR): Tuznue, trastuzumab, D...

Related Posts

Template for a European Union herbal monograph

Template for a European Union herbal monograph

Feb 17, 2025  0

Orphan designation: [4-(Methyl-1H-pyrazol-4-yl)-benzyl]-(6[7-(3-pyrrolidin-1-yl-propoxy)-imidazo[1,2-a]pyridin-3-yl]-pyrimidin-4-yl]-amine Treatment of gastrointestinal stromal tumours, 16/01/2025 Positive

Orphan designation: [4-(Methyl-1H-pyrazol-4-yl)-benzyl]...

Feb 20, 2025  0

Minutes - PDCO minutes of the 10-13 December 2024 meeting

Feb 13, 2025  0